Literature DB >> 26622445

Effect of serum from postmenopausal women with osteoporosis exhibiting the Kidney-Yang deficiency pattern on bone formation in an hFOB 1.19 human osteoblastic cell line.

Yachan Li1, Wenna Liang1, Xihai Li2, Bizhen Gao1, Huijuan Gan1, Lianhua Yin3, Jianying Shen1, Jie Kang1, Shanshan Ding1, Xuejuan Lin1, Linghong Liao1, Candong Li1.   

Abstract

The aim of the present study was to investigate the underlying mechanism of the Kidney-Yang deficiency (KYD) pattern of osteoporosis in postmenopausal women of a certain age range by comparing the effect of serum from postmenopausal women with osteoporosis exhibiting the KYD pattern with that of serum from postmenopausal women without osteoporosis on bone formation in an hFOB 1.19 human osteoblastic cell line. A random selection of 30 female, postmenopausal volunteers aged 60-70 years, including 15 cases without osteoporosis and 15 cases with the KYD pattern of osteoporosis, were enrolled at the Physical Examination Center of the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine. Venous blood was extracted and the serum was separated. The hFOB 1.19 cells were treated with 10% KYD pattern-serum or control serum from postmenopausal women of the same age range without osteoporosis. It was found that the KYD pattern-serum significantly decreased the cell viability, activity of alkaline phosphatase and number of calcified nodules, as well as downregulated the expression of osteocalcin and osteoprotegerin (OPG) and upregulated that of receptor activator of nuclear factor κB ligand (RANKL) in the hFOB 1.19 cells. In addition, the present results showed that the concentrations of estradiol (E2), OPG and insulin-like factor-1 (IGF-1) in the KYD pattern-serum were lower than those in the control serum. In combination, these findings suggest that the downregulation of E2, OPG and IGF-1 in the KYD pattern-serum inhibits the OPG/RANKL system, leading to a decrease in bone formation in the hFOB 1.19 cells. This indicates that the alterations in E2, OPG and IGF-1 may account for the susceptibility of certain postmenopausal women to the KYD pattern of osteoporosis.

Entities:  

Keywords:  Kidney-Yang deficiency pattern; bone formation; osteoblast; postmenopausal osteoporosis

Year:  2015        PMID: 26622445      PMCID: PMC4533207          DOI: 10.3892/etm.2015.2616

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  36 in total

Review 1.  Syndrome differentiation in modern research of traditional Chinese medicine.

Authors:  Miao Jiang; Cheng Lu; Chi Zhang; Jing Yang; Yong Tan; Aiping Lu; Kelvin Chan
Journal:  J Ethnopharmacol       Date:  2012-02-01       Impact factor: 4.360

2.  Tongue coating microbiome regulates the changes in tongue texture and coating in patients with post-menopausal osteoporosis of Gan-shen deficiency syndrome type.

Authors:  Wenna Liang; Xihai Li; Yachan Li; Candong Li; Bizheng Gao; Huijuan Gan; Sumin Li; Jianying Shen; Jie Kang; Shanshan Ding; Xuejuan Lin; Linghong Liao
Journal:  Int J Mol Med       Date:  2013-09-10       Impact factor: 4.101

3.  Association between tongue appearance in Traditional Chinese Medicine and effective response in treatment of rheumatoid arthritis.

Authors:  Miao Jiang; Qinglin Zha; Cheng Lu; Yiting He; Aiping Lu
Journal:  Complement Ther Med       Date:  2011-05-25       Impact factor: 2.446

4.  Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation.

Authors:  M J Coelho; M H Fernandes
Journal:  Biomaterials       Date:  2000-06       Impact factor: 12.479

5.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells.

Authors:  Seung Min Oh; Ha Ryong Kim; Kyu Hyuck Chung
Journal:  Arch Pharm Res       Date:  2008-02       Impact factor: 4.946

Review 7.  RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.

Authors:  Hisataka Yasuda
Journal:  World J Orthop       Date:  2013-10-18

8.  Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength.

Authors:  Katherine M Melville; Natalie H Kelly; Sohaib A Khan; John C Schimenti; F Patrick Ross; Russell P Main; Marjolein C H van der Meulen
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

9.  Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT.

Authors:  Cécile Mazière; Valéry Salle; Cathy Gomila; Jean-Claude Mazière
Journal:  Biochim Biophys Acta       Date:  2013-06-10

10.  The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts.

Authors:  Su Huang; Pierre P Eleniste; Kornchanok Wayakanon; Prashant Mandela; Betty A Eipper; Richard E Mains; Matthew R Allen; Angela Bruzzaniti
Journal:  Bone       Date:  2013-12-28       Impact factor: 4.398

View more
  3 in total

Review 1.  Role of Traditional Chinese Medicine in Bone Regeneration and Osteoporosis.

Authors:  Zhicai Peng; Ronghua Xu; Qinjian You
Journal:  Front Bioeng Biotechnol       Date:  2022-05-31

2.  Diosgenin inhibits Wnt/β-catenin pathway to regulate the proliferation and differentiation of MG-63 cells.

Authors:  Yunlin Ge; Shuchen Ding; Jiangbiao Feng; Jiangdong Du; Zenghui Gu
Journal:  Cytotechnology       Date:  2021-02-05       Impact factor: 2.058

3.  A polysaccharide from the dried rhizome of Drynaria fortunei (Kunze) J. Sm. prevents ovariectomized (OVX)-induced osteoporosis in rats.

Authors:  Xin Sun; Bo Wei; Zhiheng Peng; Xiaru Chen; Qinglong Fu; Chaojun Wang; Jinchang Zhen; Jiecong Sun
Journal:  J Cell Mol Med       Date:  2020-02-17       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.